A study of LL-37 for the treatmemt of venous leg ulcers
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 03 Jul 2018
At a glance
- Drugs LL 37 (Primary)
- Indications Leg ulcer
- Focus Therapeutic Use
- 03 Jul 2018 According to a ProMore Pharma media release, the Swedish Medical Products Agency has approved the companys application to start a Phase IIb study with LL-37 for treatment of venous leg ulcers (HEAL).
- 31 Oct 2017 According to a ProMore Pharma media release, has signed an agreement with CRO PCG Clinical Services regarding management of this trial and planning to provide initial efficacy data in the second half of 2019.
- 21 Sep 2017 According to a ProMore Pharma media release, the trial will be conducted in Europe with a planned start for patient enrolment in 2018.